UPADACITINIB | UPADACITINIB | ATC L04AA44
IMMUNOMODULATING A JANUS KINASE (JAK) INHIBITOR TREATMENT OF RHEUMATOID ARTHRITIS | ORAL | Tmax 3 HOUR PPB 52 PERCENT HT 11 HOUR SOLUBILITY 0.2 TO 38 MILLIGRAM / MILLILITER | JANUS KINASE (JAK) | Tyrosine-protein kinase JAK1 inhibitor P23458 JAK1_HUMAN | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |